Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for c erbB2
Most Correlated Studies
- Mammary fibrocystic disease MCF10A cells with HER, c-MYC, or HER plus c-MYC double overexpression
- Primary, metastatic and recurring breast cancers with ER, PR, HER2 status and molecular subtypes
- Breast tumors with pathologic complete response (pCR) or residual disease (RD) upon chemotherapy
- Transgenic mutation in oncogenes and tumor suppressor genes in mammary tissue
- ER+ and ER- breast cancer in patients treated preventatively with tamoxifen
Most Relevant Literature
- Inhibition of mutationally activated HER2.
- Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.
- The status of HER2 in colorectal carcinoma and the relation of HER2 with prognostic parameters and M…
- HER2 targeted therapy in colorectal cancer: New horizons.
- HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA.
Most Relevant Clinical Trials
- Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Po…
- Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Can…
- A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapati…
- Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic…
- Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Ca…
